Recent research suggests a simplified approach to HPV vaccination may considerably increase its impact worldwide. A large-scale study indicates a single dose of the HPV vaccine offers comparable protection against cervical cancer as the currently recommended two-dose schedule.This finding, reported Wednesday, could be a game-changer for vaccination efforts, particularly in regions facing logistical and financial barriers to widespread immunization [[1]].
A single dose of the human papillomavirus (HPV) vaccine appears to be as effective as two doses in preventing infection with the virus that causes cervical cancer, researchers reported on Wednesday, November 8, 2023.
HPV is a very common sexually transmitted virus. While most infections clear up on their own, some persist and can lead to cancers years later, including cervical cancer in women and rarer cancers in both men and women. The vaccine has been recommended for girls in the United States since 2006, and the country has already seen a decline in precancerous cervical changes among women in their 20s – the first age group to receive the vaccine as adolescents.
However, cervical cancer remains a significant global health concern, causing approximately 340,000 deaths annually worldwide. These new findings from a large study conducted in Costa Rica could bolster global efforts to protect more girls and young women, particularly in low-income countries with limited access to healthcare. Effective vaccination strategies are crucial for reducing the burden of HPV-related cancers globally.
The study, led by the National Cancer Institute, involved more than 20,000 girls between the ages of 12 and 16. The research suggests that simplifying the vaccination schedule to a single dose could improve vaccine uptake and broaden protection against HPV-related diseases.
